Article
GMP-Compliant iPS Cell Lines Show Widespread Plasticity in a New Set of Differentiation Workflows for Cell Replacement And Cancer Immunotherapy
Catalent’s Maria Lopez, General Manager of US Cell Therapy discusses the current state of the cell therapy market and the ways Catalent is working to overcome some of these challenges. Based on an interview conducted by, and published in, BioBuzz.
View Now
Video
Roundtable: Cell and Gene Therapy Manufacturing Panel at Advanced Therapies Week 2024
Catalent expert George Buchman, Ph.D., offers insights on key challenges with scaling up production for gene therapies, complexities in the supply chain, regulatory considerations and overall reflections on the industry, progress and future.
View Now
Article
Article: What Strategies are Being Employed to Accelerate Product Development and Commercialization Without Compromising Quality
Summary: In this article, Catalent expert Victor Vinci discusses what strategies are being employed to accelerate product development and commercialization without compromising quality.
View Now
Article
Article: How Cell and Gene Therapy Manufacturing Will Evolve in 2024
Summary: In this article, Catalent expert Rupa Pike to discusses the manufacturing requirements for a specific cell therapy gaining popularity: CAR T cell therapies.
View Now
Article
Article: What Challenges Does the Advanced Therapies Sector Face?
Summary: In this article, Catalent commented on pricing and approval of advanced therapies.
View Now
Article
Article: Scrip Asks...What Does 2024 Hold for Biopharma?
Summary: In this article, Catalent's George Buchman was asked to respond and give insight into trends across cell and gene therapy and what we can expect to witness this year.
View Now
Article
Article: Pharma Manufacturing: 2024 Pharma Predictions
Summary: In this article, Catalent expert, Victor Vinci was asked to respond and give his insight into manufacturing platforms and how they will help drugmakers meet demands.
View Now
Article
Article: Getting Gene Therapy into the Fast Lane
Summary: In this article, Catalent expert George Buchman discusses the recent increase in gene therapy approvals & how we can accelerate the manufacturing speed with platform processes.
View Now
Poster
Poster - GPEx® Lightning: Digital Control of Expression for Rapid, High-Titer Production of Complex Products in CHO Cells
A poster presentation of how Catalent's GPEx® Lightning system enables faster development timelines, robust manufacturing processes, improved titers, and higher final yields.
View Now
Podcast
From Cell Collection to Commercial Contracting: Advancements in Cell & Gene Therapy Manufacturing (Part II)
In this episode of “The Top Line”, Fierce Pharma’s Fraiser Kansteiner interviews Delara Motlagh, head of cell therapy at Catalent; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. The conversation covers cell collection, the critical first step in advanced therapy manufacturing.
View Now